Dong Ji

3.9k total citations · 1 hit paper
71 papers, 1.7k citations indexed

About

Dong Ji is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Dong Ji has authored 71 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Epidemiology, 41 papers in Hepatology and 12 papers in Molecular Biology. Recurrent topics in Dong Ji's work include Liver Disease Diagnosis and Treatment (41 papers), Hepatitis B Virus Studies (30 papers) and Hepatitis C virus research (24 papers). Dong Ji is often cited by papers focused on Liver Disease Diagnosis and Treatment (41 papers), Hepatitis B Virus Studies (30 papers) and Hepatitis C virus research (24 papers). Dong Ji collaborates with scholars based in China, United States and Hong Kong. Dong Ji's co-authors include George Lau, Guofeng Chen, Yu Wang, Gregory Cheng, Chen Zhu, Enqiang Qin, Peng Zhao, Jing Xu, Jingfeng Bi and Dawei Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Dong Ji

64 papers receiving 1.7k citations

Hit Papers

Prediction for Progression Risk in Patients With COVID-19... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score
    2020 391 citations Dong Ji, Dawei Zhang et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dong Ji China 21 804 561 479 277 218 71 1.7k
Kazufumi Dohmen Japan 24 1.1k 1.3× 913 1.6× 106 0.2× 212 0.8× 174 0.8× 96 2.0k
Shuang Bai China 18 266 0.3× 202 0.4× 100 0.2× 214 0.8× 184 0.8× 61 1.1k
Xueqin Chen China 24 225 0.3× 47 0.1× 241 0.5× 462 1.7× 304 1.4× 156 1.8k
Jielai Xia China 21 487 0.6× 458 0.8× 173 0.4× 275 1.0× 81 0.4× 83 1.6k
Chao‐Long Chen Taiwan 16 286 0.4× 421 0.8× 47 0.1× 168 0.6× 197 0.9× 57 1.6k
Danbi Lee South Korea 27 985 1.2× 1.3k 2.3× 43 0.1× 283 1.0× 437 2.0× 131 2.2k
Manish Tandon United States 26 204 0.3× 111 0.2× 87 0.2× 669 2.4× 336 1.5× 96 2.0k
Upinder Kaur India 20 184 0.2× 290 0.5× 313 0.7× 174 0.6× 53 0.2× 92 1.2k
Xiao Gong China 17 260 0.3× 98 0.2× 203 0.4× 95 0.3× 72 0.3× 41 893

Countries citing papers authored by Dong Ji

Since Specialization
Citations

This map shows the geographic impact of Dong Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong Ji more than expected).

Fields of papers citing papers by Dong Ji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong Ji. The network helps show where Dong Ji may publish in the future.

Co-authorship network of co-authors of Dong Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Dong Ji. A scholar is included among the top collaborators of Dong Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong Ji. Dong Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Rui, Zhe Wang, Lixin Cheng, et al.. (2025). Coordination of SLC39A1 and DRP1 facilitates HCC recurrence by impairing mitochondrial quality control. Clinical and Translational Medicine. 15(5). e70362–e70362.
2.
Li, Qianqian, Yüting Xiong, Kexin Wang, et al.. (2024). Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis. PubMed. 3(2). 100094–100094. 1 indexed citations
3.
Xiong, Yüting, Jianfei Wang, Yan Liu, et al.. (2024). Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury. PubMed. 3(2). 100095–100095. 2 indexed citations
4.
5.
Xiong, Yüting, Jianfei Wang, Xiao-Xia Niu, et al.. (2023). Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. Frontiers in Pharmacology. 14. 1071709–1071709. 4 indexed citations
6.
Yan, Tao, Chen‐Yang Huang, Xuezhang Duan, et al.. (2023). A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Annals of Translational Medicine. 11(2). 109–109. 5 indexed citations
7.
Wang, Jianjun, Kexin Wang, Chun Chen, et al.. (2023). Survival analysis and development of a prognostic nomogram for patients with hepatitis B virus-associated hepatocellular carcinoma. Heliyon. 9(10). e20850–e20850. 3 indexed citations
8.
Liao, Hao, Wei Zheng, Jun Zou, et al.. (2022). Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Disease Markers. 2022. 1–13. 7 indexed citations
9.
Wang, Chunyan, Ping Li, Sujun Zheng, et al.. (2021). Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study. Hepatology. 75(6). 1373–1385. 17 indexed citations
10.
Fu, Yiming, Chunyan Wang, Yan Liu, et al.. (2021). Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia. Liver International. 41(6). 1254–1264. 36 indexed citations
11.
Ji, Dong, Guofeng Chen, Xiao-Xia Niu, et al.. (2021). Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. SHILAP Revista de lepidopterología. 10. 100090–100090. 23 indexed citations
12.
Ji, Dong, Dawei Zhang, Jing Xu, et al.. (2020). Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clinical Infectious Diseases. 71(6). 1393–1399. 391 indexed citations breakdown →
13.
Ji, Yingjie, Xuezhang Duan, Xudong Gao, et al.. (2016). Clinical presentations and outcomes of patients with Ebola virus disease in Freetown, Sierra Leone. Infectious Diseases of Poverty. 5(1). 101–101. 14 indexed citations
14.
Ji, Dong, et al.. (2015). MiR-22 Suppresses BMP7 in the Development of Cirrhosis. Cellular Physiology and Biochemistry. 36(3). 1026–1036. 34 indexed citations
15.
Ji, Dong & Jin Li. (2014). Advances in the treatment of gastric cancer targeting PI3K/Akt/mTOR pathway. Tumori. 34(2). 191–196. 1 indexed citations
16.
Ji, Dong, Qing Shao, Ping Han, et al.. (2014). The Frequency and Determinants of Liver Stiffness Measurement Failure: A Retrospective Study of “Real-Life” 38,464 Examinations. PLoS ONE. 9(8). e105183–e105183. 14 indexed citations
17.
18.
Lu, Zhongtang, Zheyong Liang, Dong Ji, et al.. (2012). Metastasis-associated in colon cancer-1 is associated with poor prognosis in hepatocellular carcinoma, partly by promoting proliferation through enhanced glucose metabolism. Molecular Medicine Reports. 12(1). 426–434. 20 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazufumi Dohmen Breakdown of academic impact, for papers by Shuang Bai Breakdown of academic impact, for papers by Xueqin Chen Breakdown of academic impact, for papers by Jielai Xia Breakdown of academic impact, for papers by Chao‐Long Chen Breakdown of academic impact, for papers by Danbi Lee Breakdown of academic impact, for papers by Manish Tandon Breakdown of academic impact, for papers by Upinder Kaur Breakdown of academic impact, for papers by Xiao Gong
Rankless by CCL
2026